KMDA News

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting

Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory

Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year

Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026

VariZIG Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts 2020-2035

Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders

Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas

Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth

Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy